SEC Comment Letter 0000000000-25-003947 to Bio Green Med Solution, Inc. (BGMS)

Bio Green Med Solution, Inc.
Date: April 14, 2025 · CIK: 0001130166 · Accession: 0000000000-25-003947

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 14, 2025

Author

Division of

Form

UPLOAD

Company

Bio Green Med Solution, Inc.

Letter

Re: Cyclacel Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted April 10, 2025 CIK No. 0001130166 Dear Datuk Dr. Doris Wong Sing Ee:

April 14, 2025

Datuk Dr. Doris Wong Sing Ee Chief Executive Officer Cyclacel Pharmaceuticals, Inc. Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Debbie A. Klis

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 14, 2025

Datuk Dr. Doris Wong Sing Ee
Chief Executive Officer
Cyclacel Pharmaceuticals, Inc.
Level 10, Tower 11, Avenue 5, The Horizon
Bangsar South City, No. 8, Jalan Kerinchi, 59200
Kuala Lumpur, Malaysia

 Re: Cyclacel Pharmaceuticals, Inc.
 Draft Registration Statement on Form S-1
 Submitted April 10, 2025
 CIK No. 0001130166
Dear Datuk Dr. Doris Wong Sing Ee:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement at least
two business
days prior to the requested effective date and time. Please refer to Rules 460
and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Debbie A. Klis
</TEXT>
</DOCUMENT>

SecProbe.io